www.fdanews.com/articles/197126-nice-backs-pfizers-lorviqua-for-lung-cancer
NICE Backs Pfizer's Lorviqua for Lung Cancer
May 14, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Lorviqua (lorlatinib) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after prior treatments.
The institute said that the most likely cost-effectiveness estimates for the treatment are within what it normally considers an acceptable use of NHS resources.
NICE also said Lorviqua meets its criteria to be considered a life-extending treatment.